Two Sigma Advisers
ESPR

Two Sigma Advisers’s Esperion Therapeutics ESPR Stock Holding History

Two Sigma Advisers’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,505,200
Closed -$13M – 702
2025
Q4 		$13M Buy
3,505,200
+1,597,200
+84% +$5.16M 0.03% 465
2025
Q3 		$5.06M Sell
1,908,000
-185,700
-9% -$359K 0.01% 743
2025
Q2 		$2.06M Sell
2,093,700
-433,300
-17% -$434K ﹤0.01% 1107
2025
Q1 		$3.64M Sell
2,527,000
-1,089,200
-30% -$2.01M 0.01% 904
2024
Q4 		$7.96M Buy
3,616,200
+16,100
+0.4% +$37.6K 0.02% 550
2024
Q3 		$5.94M Sell
3,600,100
-274,200
-7% -$554K 0.01% 652
2024
Q2 		$8.6M Buy
3,874,300
+304,600
+9% +$717K 0.02% 580
2024
Q1 		$9.57M Buy
3,569,700
+1,423,100
+66% +$3.46M 0.02% 555
2023
Q4 		$6.42M Buy
2,146,600
+610,300
+40% +$792K 0.02% 703
2023
Q3 		$1.51M Buy
1,536,300
+851,268
+124% +$1.23M ﹤0.01% 1338
2023
Q2 		$952K Sell
685,032
-172,168
-20% -$240K ﹤0.01% 1556
2023
Q1 		$1.36M Sell
857,200
-558,800
-39% -$2.88M ﹤0.01% 1476
2022
Q4 		$8.82M Buy
1,416,000
+331,700
+31% +$2.37M 0.02% 556
2022
Q3 		$7.26M Buy
1,084,300
+1,070,900
+7,992% +$7.35M 0.02% 592
2022
Q2 		$85K Buy
+13,400
New +$76K ﹤0.01% 2408
2019
Q4 		– Sell
-58,400
Closed -$2.14M – 2382
2019
Q3 		$2.14M Sell
58,400
-95,400
-62% -$3.78M 0.01% 1081
2019
Q2 		$7.16M Buy
153,800
+86,300
+128% +$4.05M 0.02% 703
2019
Q1 		$2.71M Buy
67,500
+20,800
+45% +$933K 0.01% 1090
2018
Q4 		$2.15M Buy
+46,700
New +$2.25M 0.01% 1147
2018
Q2 		– Sell
-21,300
Closed -$1.54M – 2401
2018
Q1 		$1.54M Sell
21,300
-2,700
-11% -$198K ﹤0.01% 1363
2017
Q4 		$1.58M Buy
24,000
+9,200
+62% +$495K ﹤0.01% 1346
2017
Q3 		$742K Buy
+14,800
New +$714K ﹤0.01% 1597
2015
Q3 		– Sell
-63,759
Closed -$5.21M – 1852
2015
Q2 		$5.21M Buy
63,759
+41,400
+185% +$4.05M 0.04% 466
2015
Q1 		$2.07M Buy
+22,359
New +$1.44M 0.02% 752

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers's ESPR Position: Q1 2026 in Review

Two Sigma Advisers sold out of Esperion Therapeutics (ESPR) in Q1 2026, closing a stake of 3,505,200 shares — an estimated $13M sold.

Two Sigma Advisers first reported a position in ESPR in Q1 2015 and held it in 24 quarters. The position peaked at $13M in Q4 2025. 207 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Two Sigma Advisers reported no remaining Esperion Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 3,505,200 Esperion Therapeutics shares in Q1 2026, an estimated $13M.
  • Two Sigma Advisers first reported a position in Esperion Therapeutics in Q1 2015 and held it in 24 quarters.
  • Two Sigma Advisers's Esperion Therapeutics position peaked at $13M in Q4 2025.
  • 207 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.